[Depth | "Ten Years" between Wang Lei and AstraZeneca] Since Wang Lei joined AstraZeneca China in 2013, the company has continuously strengthened its strategic layout in China and is committed to in-depth cooperation with the local innovation ecosystem. According to the reporter's analysis, since 2023, AstraZeneca has reached global authorized cooperation with 10 Chinese innovative pharmaceutical companies (Biotech), with a cumulative total amount exceeding 8.5 billion US dollars. At the end of December 2023, AstraZeneca completed its wholly-owned acquisition of Genshin Biotech for $1.2 billion, marking the first time that Chinese biotech has been acquired by a foreign pharmaceutical company as a whole.